



## DAFTAR PUSTAKA

- Aberg, J.A., Lacy, C., Amstrong, L., Goldman, M. and Lance, L.L., 2009, *Drug Information Handbook 17th Edition*, American Pharmacist Association
- Alqudah, B.M., Alhusamia, H., A.odeh, A., Ataileh, L., Alawneh, Z.E., 2017. *Prevalence of Hypertension among Diabetic Type 2 Patients Attending Medical Clinic at Prince Hashem bin Abdullah Hospital in Aqaba*. Indian Journl Med. Res. Pharm. Scinences 4, 47–54.
- Alwhaibi, M., Balkhi, B., Alhawassi, T.M., Alkofide, H., Alduhaim, N., Alabdulali, R., Drweesh, H., Sambamoorthi, U., 2018. *Polypharmacy among patients with diabetes: A cross-sectional retrospective study in a tertiary hospital in Saudi Arabia*. BMJ Open 8.
- Ansari, J., 2010. *Drug interaction and pharmacist*. J. Young Pharm. 2, 326–331.
- Casadei Gardini, A., Faloppi, L., De Matteis, S., Foschi, F.G., Silvestris, N., Tovoli, F., Palmieri, V., Marisi, G., Brunetti, O., Vespasiani-Gentilucci, U., Perrone, G., Valgiusti, M., Granato, A.M., Ercolani, G., Negrini, G., Tamburini, E., Aprile, G., Passardi, A., Santini, D., Cascinu, S., Frassinetti, G.L., Scartozzi, M., 2017. *Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale*. Eur. J. Cancer 86, 106–114.
- Choi, Y.H., Kim, S.G., Lee, M.G., 2006. *Dose-Independent Pharmacokinetics of Metformin in Rats: Hepatic and Gastrointestinal First-Pass Effects*. J. Pharm. Sci. 101, 2271–2280.
- Choi, Y.H., Lee, M.G., 2012. *Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes 42*, 483–495.
- Corrie, K., Hardman, J.G., 2017. *Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics*. Anaesth. Intensive Care Med. 18, 331–334.
- Corrie, K., Hardman, J.G., 2020. *Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics*. Anaesth. Intensive Care Med. 21, 219–222.
- Dennedy, M.C., Rizza, R.A., Dinneen, S.F., 2015. *Classification and Diagnosis of Diabetes Mellitus*, Seventh Ed. ed, Endocrinology: Adult and Pediatric. Elsevier Inc.
- Dias, B.M., Dos Santos, F.S., Reis, A.M.M., 2019. *Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: Cross-sectional study*. Sao Paulo Med. J. 137, 369–378.
- do Prado, M.A.M.B., Francisco, P.M.S.B., Barros, M.B. de A., 2016. *Diabetes in the elderly: Drug use and the risk of drug interaction*. Cienc. e Saude Coletiva 21, 3447–3458.
- Dookeeram, D., Bidaisee, S., Paul, J.F., Nunes, P., Robertson, P., Maharaj, V.R., Sammy, I., 2017. *Polypharmacy and potential drug–drug interactions in*



- emergency department patients in the Caribbean. Int. J. Clin. Pharm.* 39, 1119–1127.
- Gavin, J.R., 1998. *New classification and diagnostic criteria for diabetes mellitus. Clin. Cornerstone* 1, 1–12.
- Gunaratne, K., Austin, E., Wu, P.E., 2018. *Unintentional sulfonylurea toxicity due to a drug – drug interaction : a case report* 8–11.
- Hapsari, I.W.A., 2019. *Evaluasi Interaksi Obat pada Pengobatan Diabetes Melitus Tipe 2 Pasien Geriatri di Instalasi Rawat Inap RSUD Ir. Soekarno Sukoharjo Tahun 2017*.
- Herrera, C., Triplitt, C., Garduno-Garcia, J., Adams, J., DeFronzo, R., Cersosimo, E., 2013. *Mechanisms of Glucose Lowering of Metformin in Type 2 Diabetes* 36.
- Horii, T., Iwasawa, M., Kabeya, Y., Atuda, K., 2019. *Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis. Sci. Rep.* 9, 1–6.
- International Diabetes Federation, 2015. *IDF Diabetes Atlas, the Seventh Edition*.
- Jean-Marie, E., 2018. *Diagnosis and classification of diabetes mellitus*, 2nd ed, Encyclopedia of Endocrine Diseases. Elsevier Inc.
- Kementerian Kesehatan RI, 2019. *Hari Diabetes Sedunia Tahun 2018*. Pus. Data dan Inf. Kementerian Kesehat. RI 1–8.
- Keresztes, P., Peacock-Johnson, A., 2019. *CE: Type 2 diabetes: A pharmacologic update. Am. J. Nurs.* 119, 32–40.
- Li, J., Chattopadhyay, K., Xu, M., Chen, Y., Hu, F., Wang, X., Li, L., 2019. *Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients at a tertiary care department in Ningbo, China: A retrospective database study. PLoS One* 14, 1–16.
- Manitpisitkul, P., Curtin, C.R., Wang, K.S.S., Ford, L., Heald, D.L., 2013. *An Open-Label Drug – Drug Interaction Study of the Steady-State Pharmacokinetics of Topiramate and Glyburide in Patients with Type 2 Diabetes Mellitus* 929–938.
- Micheli, L., Sbrilli, M., Nencini, C., 2012. *Severe hypoglycemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports. Int. J. Clin. Pharmacol. Ther.* 50, 302–306.
- Minks, J., 2020. *A theoretical framework to guide a study for exploring the impact of established and potential risk factors for type 2 diabetes mellitus. Appl. Nurs. Res.* 53, 151267.
- Niu, J., Straubinger, R.M., Mager, D.E., 2019. *Pharmacodynamic Drug–Drug Interactions. Clin. Pharmacol. Ther.* 105, 1395–1406.
- Nurlaelah, I., Mukaddas, A., Faustine, I., 2015. *Kajian Interaksi Obat Pada Pengobatan Diabetes Melitus (Dm) Dengan Hipertensi Di Instalasi Rawat Jalan Rsud Undata Palu* 35–41.
- Olokoba, A.B., Obateru, O.A., Olokoba, L.B., 2015. *Type 2 Diabetes: a Review of Current Trends -. Int. J. Curr. Res. Rev.* 7, 61–66.
- Omar, S.M., Musa, I.R., ElSouli, A., Adam, I., 2019. *Prevalence, risk factors, and glycaemic control of type 2 diabetes mellitus in eastern Sudan: a community-based study. Ther. Adv. Endocrinol. Metab.* 10, 1–8.



- Padhi, S., Nayak, A.K., Behera, A., 2020. *Type II diabetes mellitus: a review on recent drug based therapeutics*. Biomed. Pharmacother. 131, 110708.
- Pfeiffer, A.F.H., Klein, H.H., 2014. *Therapie des diabetes mellitus typ 2*. Dtsch. Arztebl. Int. 111, 69–82.
- Pradifta, R., 2019. *Kajian Interaksi Obat Antidiabetik Dengan Obat Lain Pada Pasien Diabetes Mellitus Rawat Inap Di Rsud Dr. Soekardjo Tasikmalaya*, 88–93.
- Punthakee, Z., Goldenberg, R., Katz, P., 2018. *Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome*. Can. J. Diabetes 42, S10–S15.
- Ramírez-espejel, C.J., Juárez-cedillo, T., Annia, M., 2017. *Prevalence and Risk Factors of Potential Drug-Drug Interactions in Older Adults Treated in Primary Health Care*. Ann Public Heal. Res 4, 1067.
- Ren, W., Liu, Y., Zhang, J., Fang, Z., Fang, H., Gong, Y., Lv, X., 2020. *Prevalence of potential drug–drug interactions in outpatients of a general hospital in China: a retrospective investigation*. Int. J. Clin. Pharm. 42, 1190–1196.
- Saibi, Y., Hasan, D., Shaqila, V., 2018. *Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit X Tangerang Selatan*. J. Manaj. dan Pelayanan Kefarmasian 8, 100–104.
- Sesti, G., Antonelli Incalzi, R., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., Ferrara, N., 2018. *Management of diabetes in older adults*. Nutr. Metab. Cardiovasc. Dis. 28, 206–218.
- Shetty, V., Chowta, M.N., Chowta K, N., Shenoy, A., Kamath, A., Kamath, P., 2018. *Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital*. J. Aging Res. 2018.
- Sinaga, F., 2010. *Interaksi Farmakokinetika Pada Distribusi Obat*. J. Pengabd. Kpd. Masy.
- Soelistijo, S., Novida, H., Rudijanto, A., Soewondo, P., Suastika, K., Manaf, A., Sanusi, H., Lindarto, D., Shahab, A., Pramono, B., Langi, Y., Purnamasari, D., Soetedjo, N., 2015. *Konsesus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe2 Di Indonesia 2015*, Perkeni.
- Wen, J., Zeng, M., Liu, Z., Zhou, H., Xu, H., 2019. *The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics* 139, 37–41.
- White, J.R., Campbell, R.K., 2000. *Dangerous and common drug interactions in patients with diabetes mellitus*. Endocrinol. Metab. Clin. North Am. 29, 789–801.
- Wu, H.Y., Chiang, C.W., Li, L., 2014. *Text mining for drug-drug interaction*, Methods in Molecular Biology.
- Yamaguchi, M., Saji, T., Mita, S., Kulmatycki, K., Furihata, K., Sekiguchi, K., 2013. *Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes* 51, 641–652.